Final Glance: Biotechnology companies
AP - Tue Aug 12, 5:11PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Tue Aug 12, 12:47PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Aug 12, 11:14AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna
PR Newswire - Tue Aug 12, 7:40AM CDT
Today, Analysts Review released its research reports regarding Actavis PLC (NYSE: ACT), UnitedHealth Group Inc. (NYS: UNH), Bristol-Myers Squibb Co. (NYSE: BMY), Celgene Corporation (NASDAQ: CELG) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5652-100free.
Jim Cramer's 'Mad Money' Recap: Controlling Your Destiny
at The Street - Mon Aug 11, 7:03PM CDT
When you can't spur growth internally, you can make an acquisition, Cramer says.
Celgene Earnings In Retrospect: Up 0.4% in the Last 18 Days (CELG)
Comtex SmarTrend(R) - Mon Aug 11, 11:39AM CDT
18 days ago, on July 24th, 2014, Celgene (NASDAQ:CELG) reported its earnings. Analysts, on average, expected earnings of $0.89 per share on sales of $1.8 billion. The company actually reported EPS of $0.90 on sales of $1.9 billion, beating EPS estimates by $0.01 and beating revenue estimates by $27.6 million. Since the company's report, shares of Celgene have risen from $86.19 to $86.51, representing a gain of 0.4% in the past 18 days.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Aug 08, 7:15PM CDT
Cramer's watching earnings next week as he seeks stocks worth buying, not selling, in this market.
Celgene Shares Up 15.6% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Fri Aug 08, 9:51AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 15.64% as of today's recent price of $85.50.
Mylan Misses Q2 Earnings and Sales Estimates, Adjusts View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 10:15AM CDT
Mylan's (MYL) second quarter earnings fell short of the Zacks Consensus Estimate by a penny.
Health Canada Approves ABRAXANE® Plus Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Cancer
CNW Group - Wed Aug 06, 7:00AM CDT
High unmet need addressed with first new approved treatment in eighteen years
ClearBridge Value: Making It A Top Mutual Fund Again
at Investor's Business Daily - Tue Aug 05, 5:30PM CDT
How do you follow a legend? That's been one of the challenges for Sam Peters, who has been lead manager of $2.7 billion ClearBridge Value since taking the baton from Bill Miller about two years ago. Miller -- who still runs $2.1 billion Legg Mason...
Amgen's Multiple Myeloma Drug Kyprolis Succeeds - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 5:21PM CDT
Amgen (AMGN) intends to submit regulatory applications based on this study in the first half of 2015.